Comparison · NCT02932306-sae
IDP-121 Lotion vs IDP-121 Vehicle Lotion: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IDP-121 Lotion vs IDP-121 Vehicle Lotion: serious adverse events. Trial comparisons, record NCT02932306-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02932306-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0132 | 0.00566 | 0.0306 | wilson | |
| Risk in group 2 | 0.00519 | 0.00143 | 0.0187 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00803 | -0.00748 | 0.0258 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.55 | 0.497 | 13 | log | |
| Odds ratio, group 1 over group 2 | 2.57 | 0.495 | 13.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on IDP-121 Lotion than on IDP-121 Vehicle Lotion | 124 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IDP-121 Lotion | IDP-121 lotion (tretinoin 0.05%) was applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks. | 5 | 378 | EG000 |
| Group 2 | IDP-121 Vehicle Lotion | IDP-121 lotion vehicle was applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks. | 2 | 385 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline (Day 0) up to Week 12
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
- NCT number
- NCT02932306
- Phases
- PHASE3
- Conditions
- Acne
- Interventions
- IDP-121 Lotion, IDP-121 Vehicle Lotion
- Lead sponsor
- Bausch Health Americas, Inc.
- Results first posted
- 2020-01-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02932306?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02932306-sae